Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement

Catalent gains global rights to evaluate certepetide and its analogs for use as SMARTag ® payloads across multiple ADCs designed to address difficult-to-treat diseases Catalent’s preclinical study results provide proof-of-concept support for leveraging certepetide-related biology through its use as